Previous 10 | Next 10 |
ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021. “In 2021...
Stereotaxis (NYSE:STXS) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open. The consensus EPS Estimate is -$0.04 and the consensus Revenue Estimate is $7.66M (+12.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions an...
The following slide deck was published by Stereotaxis, Inc. in conjunction with this event. For further details see: Stereotaxis Inc. (STXS) Investor Presentation - Slideshow
"Stereotaxis reminds me in many ways of Intuitive Surgical in our early years." - Executive VP & CMO of Intuitive Surgical and new Stereotaxis board member. Innovation Day showcased significant catalysts ahead including multiple regulatory milestones & commercial product launc...
ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic e...
ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Ex...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...
ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Usi...
ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentat...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...